May 6, 2021May 6, 2021
Longeveron’s Stem Cell Therapy Shows Potential in Phase 1 Trial
News
Longeveron’s Lomecel-B, an investigational bone marrow-derived medicinal signaling cell (MSC), showed an ability to slow cognitive decline and the loss of ... Read more
May 3, 2021April 29, 2021
By Getting Involved, You Can Help Find a Cure for Alzheimer’s
Columns, Treading Dark Waters - a Column by Ray Burow
Dementia is potentially preventable in more than a third of reported cases, according to the Alzheimer’s Association. This is encouraging, ... Read more
May 3, 2021May 3, 2021
FDA Places Gene Therapy LX1001 on Fast Track
News
LX1001, a gene therapy for Alzheimer’s disease being developed by Lexeo Therapeutics, has been granted fast track designation by the ... Read more
April 29, 2021April 29, 2021
#AANAM – Nuplazid Not Linked to Side Effects Common to Antipsychotics
News
Acadia Pharmaceuticals’ Nuplazid (pimavanserin) — which is being evaluated as a potential treatment for hallucinations and delusions associated with dementia-related ... Read more
April 26, 2021April 22, 2021
Tough Love Helps Protect Loved Ones with Alzheimer’s
Columns, Treading Dark Waters - a Column by Ray Burow
Loss accompanies Alzheimer’s disease and may create animosity between a caregiver and the person receiving care. A parent or spouse ... Read more
April 26, 2021April 26, 2021
Movement Gets Youth Involved in Alzheimer’s Advocacy, Education
News
Alzheimer’s disease is not often seen among those younger than 65, but the Youth Movement Against Alzheimer’s is getting young ... Read more
April 23, 2021April 23, 2021
#AANAM – EMBARK Trial to Again Test Safety, Efficacy of Aducanumab
News
A new Phase 3 clinical trial, called EMBARK, will evaluate the long-term safety and efficacy of aducanumab (BIIB037), an investigational ... Read more
April 22, 2021April 23, 2021
#AANAM – Lecanemab Safely, Quickly Lowers Amyloid Clumps in Trial
News
Eisai and Biogen’s experimental therapy lecanemab (BAN2401) safely leads to rapid and sustained reductions in the brain levels of beta-amyloid ... Read more
April 19, 2021April 15, 2021
These Signs May Indicate Early Dementia or Alzheimer’s Disease
Columns, Treading Dark Waters - a Column by Ray Burow
While aging is the greatest risk factor associated with Alzheimer’s disease, the disease is not a normal part of aging. ... Read more
April 19, 2021April 19, 2021
Greater Support for Dementia Patients Needed Across Europe, Report Says
News
Despite minor improvements in recent years, the availability of care for people with dementia in Europe is largely inadequate, according ... Read more
April 15, 2021April 15, 2021
Safety Seen in Trial of Oral Treatment, Anavex 2-73, for Early Alzheimer’s
News
Following a positive review of preliminary data, an independent board recommended the Phase 2b/3 study investigating oral Anavex 2-73 (blarcamesine) in people ... Read more
April 12, 2021April 8, 2021
Alzheimer’s Disease, Clinical Trials, and You
Columns, Treading Dark Waters - a Column by Ray Burow
The Alzheimer’s Association cites recruitment for clinical trials, and then retaining those recruits, as one of the greatest obstacles to ... Read more

Author Details

Joe Pierce

May 6, 2021May 6, 2021

Longeveron’s Stem Cell Therapy Shows Potential in Phase 1 Trial

News

Longeveron’s Lomecel-B, an investigational bone marrow-derived medicinal signaling cell (MSC), showed an ability to slow cognitive decline and the loss of daily life abilities in patients with mild Alzheimer’s disease relative to those given ... Read more

May 3, 2021April 29, 2021

By Getting Involved, You Can Help Find a Cure for Alzheimer’s

Columns, Treading Dark Waters - a Column by Ray Burow

Dementia is potentially preventable in more than a third of reported cases, according to the Alzheimer’s Association. This is encouraging, and also surprising. It is hopeful news for anyone who ... Read more

May 3, 2021May 3, 2021

FDA Places Gene Therapy LX1001 on Fast Track

News

LX1001, a gene therapy for Alzheimer’s disease being developed by Lexeo Therapeutics, has been granted fast track designation by the U.S. Food and Drug Administration (FDA). The therapy is designed ... Read more

April 29, 2021April 29, 2021

#AANAM – Nuplazid Not Linked to Side Effects Common to Antipsychotics

News

Acadia Pharmaceuticals’ Nuplazid (pimavanserin) — which is being evaluated as a potential treatment for hallucinations and delusions associated with dementia-related psychosis — is not associated with common motor side effects ... Read more

April 26, 2021April 22, 2021

Tough Love Helps Protect Loved Ones with Alzheimer’s

Columns, Treading Dark Waters - a Column by Ray Burow

Loss accompanies Alzheimer’s disease and may create animosity between a caregiver and the person receiving care. A parent or spouse receiving care may become frustrated with their loss of independence, ... Read more

April 26, 2021April 26, 2021

Movement Gets Youth Involved in Alzheimer’s Advocacy, Education

News

Alzheimer’s disease is not often seen among those younger than 65, but the Youth Movement Against Alzheimer’s is getting young people involved with the neurological disorder through volunteer work, education, ... Read more

April 23, 2021April 23, 2021

#AANAM – EMBARK Trial to Again Test Safety, Efficacy of Aducanumab

News

A new Phase 3 clinical trial, called EMBARK, will evaluate the long-term safety and efficacy of aducanumab (BIIB037), an investigational therapy for Alzheimer’s disease in patients who took part in its ... Read more

April 22, 2021April 23, 2021

#AANAM – Lecanemab Safely, Quickly Lowers Amyloid Clumps in Trial

News

Eisai and Biogen’s experimental therapy lecanemab (BAN2401) safely leads to rapid and sustained reductions in the brain levels of beta-amyloid — the protein that forms toxic clumps in Alzheimer’s — ... Read more

April 19, 2021April 15, 2021

These Signs May Indicate Early Dementia or Alzheimer’s Disease

Columns, Treading Dark Waters - a Column by Ray Burow

While aging is the greatest risk factor associated with Alzheimer’s disease, the disease is not a normal part of aging. Most people with Alzheimer’s are 65 or older. But this ... Read more

April 19, 2021April 19, 2021

Greater Support for Dementia Patients Needed Across Europe, Report Says

News

Despite minor improvements in recent years, the availability of care for people with dementia in Europe is largely inadequate, according to a new report. The report, “Dementia Monitor 2020,” was ... Read more